Cell And Gene Therapy Innovations

A #Breakthrough Year for T Cells This year has been transformative for T cell therapies in the fight against cancer, as reviewed by Rigel Kishton and me in today’s issue of Nature Cancer (https://rdcu.be/d3R8D). With three FDA approvals, 2024 has underscored the clinical power of #Tcells -- living #immunotherapies capable of achieving results where all other treatments fail. Key Approvals of 2024 -> #Lifileucel (Amtagvi): The first #TIL-based therapy for unresectable/metastatic melanoma, approved in February. -> Afamitresgene (Tecelra): The first #TCR-engineered therapy for solid tumors, approved in August for synovial sarcoma. -> Obecabtagene (Aucatzyl): The 7th #CAR T therapy for B cell hematologic malignancies, approved last month. 🚀 These therapies are clinically remarkable. Engineered from a patient’s own T cells, they deliver life-changing responses for patients with no other options. I’ve had the privilege of contributing to these advancements and witnessing their profound impact. The Promise of TIL Therapies TIL-based therapies hold transformative potential. By recognizing tumor #neoantigens -- expressed #mutations, cancer germline antigens, and even “#darkgenome” products like #HERVs or #pseudogenes -- T cells can achieve durable, complete responses. CD4+ and CD8+ T cells bring the ability to directly or indirectly eliminate tumors where traditional therapies fall short. Despite these advances, the oncology capital markets remain skeptical. Cell therapy companies face immense challenges: -> Development Costs: Complex manufacturing, high trial expenses, and stringent regulations. -> Safety Concerns: Risks like cytokine release syndrome and lymphodepletion-associated toxicities. -> Commercialization Hurdles: High prices, uncertain reimbursement, and cumbersome logistics. The result? T cell-based immunotherapies can land with a thud from investors concerned about small target markets and costly treatment delivery. ⚡ Technology as a Solution The future of T cell-based therapies looks brighter with technological innovation: -> #AI/ML for Transcriptomics and Genomics: Personalizing T cell products for individual patients. -> Cheaper #Sequencing: Accelerating tumor neoantigen target discovery. -> Improved Culture Methods: Enhancing T cell #stem cell qualities for durable efficacy. While #Tcellengagers and #bispecificantibodies gain investor interest for their transient solid tumor activity, these treatments are rarely curative. TIL therapies, on the other hand, stand on the cusp of delivering transformative, long-term responses in patients with common solid tumors. The journey isn’t easy—financial skepticism, logistical hurdles, and scientific complexity remain—but the horizon for T cell therapies is filled with extraordinary possibility. Here’s to the progress we've made and the breakthroughs that lie ahead. 🎇 #immunotherapy #celltherapy #carT #TIL #oncology

Just out in Science (2025)—a landmark study by Christina Jackson et al. identifies a previously uncharacterized immune cell population in human glioblastoma (GBM), termed early myeloid-derived suppressor cells (E-MDSCs). (Michael Lim, CHETAN BETTEGOWDA, Hongkai Ji, Drew Pardoll) These E-MDSCs uniquely infiltrate IDH-wild-type GBM, precisely colocalizing with glioma stem-like cells (GSCs) within pseudopalisading regions—distinct zones known for hypoxia, aggressive invasion, and treatment resistance. Strikingly, the authors uncovered a novel bidirectional signaling axis: GSCs recruit E-MDSCs by secreting specific chemokines, while E-MDSCs reciprocate by releasing potent growth factors (notably FGF11) that drive tumor proliferation via the FGF11-FGFR1 signaling pathway. Importantly, this critical tumor–immune interaction is entirely absent in IDH-mutant gliomas, due to epigenetic silencing of essential chemokine genes. This discovery not only advances our fundamental understanding of glioblastoma biology but also highlights promising new therapeutic targets specifically tailored for IDH-WT GBM—opening a vital new chapter in treating this notoriously aggressive and therapy-resistant cancer. Penn Medicine, University of Pennsylvania Health System, Johns Hopkins Medicine, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Kimmel Cancer Center

Researchers at Johns Hopkins University have created a revolutionary protein “switch” that tricks cancer cells into manufacturing their own chemotherapy drugs, causing them to self-destruct while sparing healthy cells. Instead of delivering drugs directly to cancer cells, this method uses a harmless “prodrug” that only becomes activated inside cancer cells when the switch detects specific cancer markers. The switch is made by combining two proteins: one that senses cancer markers and another from yeast that converts the inactive prodrug into a potent cancer-killing drug. When the switch detects cancer, it activates the drug inside that cell, turning the cancer cell into a drug factory that destroys itself. To work, the switch must enter cancer cells either by delivering the protein itself or by inserting the gene that makes the protein, allowing the cancer cell’s own machinery to produce the switch. Afterward, patients receive the inactive chemotherapy prodrug, which becomes activated only inside cancer cells. This new approach focuses on producing the drug inside cancer cells rather than just delivering it to them, which could kill more cancer cells while reducing harmful side effects on healthy tissue. Lab tests on human colon and breast cancer cells have shown promise, and animal testing is expected to start within a year. While still early, this technique offers a radically different way to attack cancer. #PNAS #RMScienceTechInvest

🚨 Major News in Gene Therapy: The U.S. FDA has approved Otarmeni, a gene therapy from Regeneron Pharmaceuticals Inc, for the treatment of a rare genetic form of hearing loss caused by mutations in the OTOF gene. Key Highlights: - First-ever gene therapy approved for genetic hearing loss - Targets otoferlin-related deafness (OTOF gene mutation) - Works by delivering a functional copy of the OTOF gene to inner ear cells - Uses a modified viral vector delivered directly into the cochlea - Addresses a rare condition affecting ~20–50 newborns per year in the U.S. Why it matters: ✔ Marks a historic first for gene therapy in sensory disorders ✔ Shifts the treatment paradigm from managing hearing loss → correcting its genetic cause ✔ Opens the door for broader applications of inner-ear and CNS gene delivery technologies ✔ Signals accelerating momentum in precision medicine for ultra-rare diseases ✔ Therapy is expected to be made available free to U.S. patients What a day for gene therapy. Certainly a significant milestone for patients, Regeneron - bringing functional hearing restoration closer to reality for children born with inherited deafness. #genetherapy #pharma #biotech #CGTweekly

Autologous vs. Allogeneic: A Paradigm Shift in Clinical Impact While autologous cell therapies (patient-specific) have demonstrated remarkable efficacy (90%+ in indications like B-cell malignancies), their limitations are increasingly untenable: weeks-long manufacturing delays, 10–15% production failures, and costs exceeding $500K. These bottlenecks restrict patient access, particularly in rapidly progressing diseases or resource-limited settings. 2025: The Allogeneic Tipping Point Next-generation allogeneic "off-the-shelf" therapies are poised to dominate the cell therapy landscape, driven by three transformative advancements: 1) Immune Evasion Breakthroughs: CRISPR-Cas9 and base-editing technologies (e.g., Beam Therapeutics’ cytosine base editing) enable precise disruption of HLA and TCR genes, reducing immune rejection risks. Clinical data from Allogene Therapeutics’ ALPHA2 trial (NCT04416984) show 76% objective response rates in relapsed/refractory lymphoma, mirroring autologous CAR-T outcomes. 2) Elimination of GvHD: Tools like TALEN-edited cells (Cellectis’ UCART19) report 0% Grade 3–4 GvHD in pediatric B-ALL patients (NCT02808442), with durability extending to 24+ months. 3) Scalable Manufacturing: Automated closed-system bioreactors (Lonza’s Cocoon®) and master cell banks reduce batch variability by 85% and costs by ~60% (per-dose estimates: 150K vs. 150 K vs. 400K for autologous). - Recent trials underscore allogeneic therapies’ expanding utility: 1) Solid Tumors: CRISPR Therapeutics’ CTX110 (anti-CD19 allogeneic CAR-T) achieved 57% CR rates in CD19+ B-cell malignancies (Phase 1, ASH 2022). 2) Autoimmune Diseases: Cabaletta Bio’s DSG3-CAART (for pemphigus vulgaris) eliminated pathogenic antibodies in 100% of Phase 1 patients (NCT04422912). 3) Acute Indications: Atara Biotherapeutics’ tabelecleucel (off-the-shelf EBV T-cell therapy) delivered 50% 1-year survival in post-transplant lymphoproliferative disorder (PTLD), addressing urgent unmet needs. - Market Landscape: A $23.6B Opportunity by 2030, fueled by: 1) Pipeline Expansion: 250+ allogeneic candidates in clinical trials (60% in oncology, 25% in autoimmune diseases). 2) Regulatory Tailwinds: FDA RMAT designation granted to 15 allogeneic programs (e.g., Precision Biosciences’ PBCAR0191), accelerating pathways to approval. 3) The ability to treat 10–100x more patients per batch vs. autologous therapies creates a winner-takes-most market dynamic. Don’t wait for the market to mature—dominate the inflection point. What are your thoughts? I read you in the comments ____________________________________________________________________________ 🔔 Follow for insights ♻️ Share if you find it interesting #celltherapy #biotech #investment #investor

TCR-T cell therapy – the next modality to watch?? Until recently, cell therapy has largely meant CAR-T, especially in hematologic malignancies. But TCR-T offers something different: ✅ The ability to target intracellular tumor antigens ✅ Access to shared and neoantigen targets in solid tumors ✅ Growing clinical success, with approvals finally landing In recent times, we've seen a promising acceleration in progress - and a diverse field of players driving it forward: 🧬 Adaptimmune made history with the first-ever FDA approval of a TCR-T therapy (afamitresgene autoleucel / Tecelra) for synovial sarcoma. 🧬 Immatics entered a randomized Phase 3 trial with IMA203 for melanoma, with durable 50%+ ORRs in earlier trials. 🧬 Affini-T Therapeutics, TScan Therapeutics, and T-knife Therapeutics are taking aim at KRAS, HPV, PRAME, and MAGE antigens - all deep in the clinic. 🧬 Neogene Therapeutics (now part of AstraZeneca) is pioneering personalized TCR-T with up to 5 TCRs per patient. 🧬 Medigene AG (despite financial challenges) got IND clearance for its armored NY-ESO-1 TCR-T (MDG1015). 🧬 Immunocore validated the modality with tebentafusp - the first approved TCR biologic for uveal melanoma. 🧬 BlueSphere Bio, Lion TCR, T-Cure Bioscience, Inc, and Zelluna are pushing new boundaries - from viral cancers to TCR-NK cell therapies. 🧬 Alaunos Therapeutics may be paused, but its NCI-linked mutation-targeting TCRs showed 87% DCR in refractory tumors. 🧬 Pan Cancer T, Captain T Cell, Engimmune Therapeutics, and Anocca are among the innovators building toward first-in-human trials. 🧬 Repertoire Immune Medicines, 3T Biosciences, T-Therapeutics Ltd, and Exogene are emerging with precision discovery platforms. And big pharma isn’t sitting idle: 💼 AstraZeneca (via Neogene Therapeutics), Bristol Myers Squibb (Immunocore, Juno legacy), GSK, Genentech (partnered with Adaptive Biotechnologies Corp.), Takeda, Astellas Pharma, and Boehringer Ingelheim are all backing TCR-T, often via targeted partnerships and acquisitions. The big picture? ➡️The TCR-T market is still early but growing fast - with >80 companies now active and over 100 candidates in development. ➡️ Targets like PRAME, MAGE, NY-ESO-1, KRAS, and TP53 are seeing broad traction. ➡️ Innovations like armored TCRs, off-the-shelf platforms, and TCR-NK hybrids are tackling the big bottlenecks in the field. ➡️ TCR-T might not be as well-known as CAR-T yet - but the science, the strategy, and the investor interest all suggest it's coming up fast. If you’re not watching this space yet - now might be the time. Have I missed any TCR-T companies worth spotlighting? 👇 What’s your take on TCR-T therapy’s trajectory? #TCRT #celltherapy #biotech #immunotherapy #oncology #solidtumors #biopharma #clinicaltrials #biotechstrategy #drugdevelopment

Imagine gene therapy treatments costing $100,000 instead of $2 million per dose. A new review shows this isn't just wishful thinking – continuous bioprocessing could reduce manufacturing costs by up to 80%, potentially transforming patient access to these life-changing treatments. A exciting review paper by Lorek et al. reveals how the shift from traditional batch processing to continuous manufacturing may revolutionize gene therapy production. The innovation lies in running multiple production steps simultaneously with constant material flow, enabled by multi-column chromatography systems and advanced process analytic technology (PAT). What makes this particularly exciting is how continuous processing addresses the core challenges of gene therapy manufacturing. Traditional batch processing requires larger facilities, faces significant downtime between batches, and struggles with consistency. In contrast, continuous processing achieves higher productivity at a smaller scale while improving product quality – critical factors for reducing those astronomical million-dollar-plus treatment costs. The technology behind this transformation is fascinating. Multi-column chromatography systems now enable continuous capture and purification of viral vectors, improving productivity nearly threefold while maintaining yields above 82%. Even more impressive is the integration of real-time monitoring through process analytical technologies. These systems use in -line spectroscopic sensors, dynamic light scattering, and rapid analytics to track critical quality attributes in real-time, ensuring consistent product quality while dramatically reducing manufacturing time and costs. The implications for patient care are profound. By reducing facility footprint, increasing productivity, and improving product quality, continuous processing could help transform gene therapies from last-resort options into more widely accessible treatments. Early studies suggest manufacturing costs could drop by 60-80% compared to traditional batch processing – a game-changing reduction that could dramatically expand patient access. What excites me most is how these advances are converging with artificial intelligence and automation. Real-time monitoring systems coupled with advanced process controls are enabling unprecedented precision in manufacturing, ensuring every batch meets the highest quality standards while maximizing efficiency. We're witnessing a fundamental shift in how gene therapies are manufactured. The question isn't just about cost reduction – it's about reimagining production to make these transformative treatments accessible to everyone who needs them. What are your thoughts on these developments? How do you see these manufacturing innovations reshaping the future of genetic medicine? #GeneTherapy #Biotechnology #ContinuousProcessing #Healthcare #Innovation #PatientAccess

Exciting News in the Fight Against Glioblastoma! I'm thrilled to share groundbreaking findings from the ongoing Phase I clinical trial led by researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine, University of Pennsylvania Health System Abramson Cancer Center. Their research, recently published in Nature Medicine (Nature Portfolio), demonstrates promising results in the battle against recurrent #glioblastoma (GBM), a formidable form of brain cancer. 🎯 Targeting not one, but TWO brain tumor-associated proteins with CAR T cell therapy has shown significant potential in reducing solid tumor growth among patients with recurrent GBM. This innovative "dual-target" approach marks a crucial step forward in developing effective, enduring therapies for challenging solid tumors like GBM. 🔬 Led by Dr. Stephen Bagley and Dr. Donald O'Rourke, the trial focuses on harnessing the patient's own immune system to combat cancer. By reprogramming T cells to recognize specific cancer proteins, researchers aim to outsmart the complex defense mechanisms of GBM. 🔍 The trial's method involves delivering CAR T cells targeting two proteins—EGFR and IL13Rα2—directly into the cerebrospinal fluid. Early MRI scans have shown promising results, with reduced tumor sizes observed in all six patients, indicating the potential efficacy of this approach. 📈 While challenges such as tumor heterogeneity and immune evasion persist, these findings offer hope for advancing personalized treatments tailored to individual patients' unique GBM profiles. 💡 The trial not only sheds light on the therapeutic potential of CAR T cell therapy but also underscores the importance of ongoing research in understanding and combating neurotoxicity, a significant concern in brain-targeted therapies. For more information on this groundbreaking research and ongoing clinical trials, visit the links below: 🔗 CAR T Research at Penn Medicine: https://lnkd.in/eJaTEuGq 🔗 Glioblastoma Research and Clinical Trials at Penn Medicine: https://lnkd.in/edREzq-Q Kudos to the dedicated researchers and collaborators for their tireless efforts in the fight against GBM! Let's continue to support and amplify efforts aimed at conquering this formidable foe. Together, we can make strides towards a future with improved outcomes for patients battling brain cancer. #GBMResearch #CARTtherapy #MedicalInnovation 🎉🧠🔬 https://lnkd.in/en7bfPVF

What if the future of CAR-T therapy isn’t just faster... but smarter? At the Boston Society Gene & Cell Therapy Conference, Dr. Bruce Levine made a powerful observation: “There aren’t enough humans on Earth to meet the patient demand if we continue relying solely on ex vivo CAR-T manufacturing.” Let that sink in. As cell and gene therapy pushes into glioblastoma, autoimmune diseases, and fibrosis, the scalability challenge becomes urgent. The next frontier? In vivo CAR-Ts—off-the-shelf, lipid nanoparticle (LNP)-delivered mRNA encoding CAR constructs. Think: CAR-T meets mRNA vaccine. Penn’s team has already shown targeted LNPs can engineer T cells inside the body, without preconditioning chemo, and drive potent B cell depletion in primate models. Why this matters: ✅ Scalability: 1-day production vs. 10 ✅ Access: Reduced cost, fewer barriers ✅ Precision: Direct delivery to immune cells ✅ Speed: On-demand, in vivo programming Could this approach finally unlock CAR-T for solid tumors and autoimmune conditions—at global scale? Question for you: What’s the biggest obstacle for in vivo CAR-T becoming standard: regulatory mindset, delivery technology, or long-term safety data? #CellTherapy #CART #InVivoTherapies #LNPtechnology

🦠 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐡𝐚𝐩𝐩𝐞𝐧𝐢𝐧𝐠 𝐢𝐧 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐜𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲? 🦠 In the past few months, we’ve seen: 📉 Carvykti receiving a boxed warning after approval 📉 Global players withdrawing or scaling-back cell therapy programs (Novo Nordisk & Takeda)    📉 Early clinical assets with promising data struggling to find funding or buyers (Galapagos) Headlines seem pretty bleak, but there’s a clear disparity: 𝗘𝘅 𝘃𝗶𝘃𝗼 𝘃𝘀 𝗶𝗻 𝘃𝗶𝘃𝗼 In vivo is gaining strong momentum: 📈 Major buy-in from global players (Gilead/Kite & Interius + Pregene, Abbvie & Umoja, AstraZeneca & EsoBiotec, BMS & Orbital) 📈 US governmental body ARPA-H pumping millions into in vivo cell therapy programs (Kernal Bio, ImmunoVac & Cytiva) 📈 Multiple new companies entering the race. 𝙒𝙝𝙮 𝙖𝙧𝙚 𝙬𝙚 𝙨𝙚𝙚𝙞𝙣𝙜 𝙩𝙝𝙞𝙨? Ex vivo therapies, while proven to work, come with a myriad of complexities. Complex and expensive manufacturing, long turnaround times, limited scalability and cell exhaustion to name just a few. These complexities add up. And it seems as though there’s a new kid on the block that promises a faster, cheaper and more scalable option. Some analysts project that in vivo approaches could reduce overall therapy costs several-fold. Investors and big pharma are seeing potential for higher yield from their input. 𝘿𝙤𝙚𝙨 𝙩𝙝𝙞𝙨 𝙢𝙚𝙖𝙣 𝙩𝙝𝙖𝙩 𝙚𝙭 𝙫𝙞𝙫𝙤 𝙬𝙞𝙡𝙡 𝙗𝙚 𝙤𝙪𝙨𝙩𝙚𝙙? Not exactly. There are pros and cons to either approach: Ex vivo: Best for precise, heavily engineered, or expanded cells (B-cell malignancies, rare genetic disorders, multi-gene therapies etc.) In vivo: Best for speed, scalability, and physiological cell programming (autoimmune diseases, blood disorders, emerging solid tumor CAR-Ts etc.) In vivo is still unproven. We’ll likely see consolidation on delivery approaches and indications over time. There's a clear shift toward the rising star, which is great that innovation is being supported, but it’s likely that these two approaches will need to coexist to give patients the best options. Ex vivo has some work to do to remain competitive, but I feel that this is achievable with automation, improved reagents, cell preservation, bioreactor systems etc. to minimise the cost and complexity to ensure it remains the gold standard where precision matters most. What are your thoughts? #mCGT #celltherapy #advancedtherapies #ATMP #biotech